Ann: MND Trial Successfully Completes First Patient Cohort, page-45

No wonder its hard to find existing MND patients who fit the criteria for the PAA MND trial - 107 patients already involved in other trials trials (2022)

Fight MND trials
1. PROJECThase 3 Clinical Trial – Randomised double-blind placebo-controlled Phase3 trial of Lithium Carbonate in MND, a sub-study of a Multi-arm, Adaptive, Group- sequential trial NETwork to evaluate drug efficacy in patients with MND (MAGNET)

• The Australian arm of this phase 3 trial aims to enrol 57 patients at 7 sites across Australia in Sydney, Adelaide, Perth, Brisbane and Melbourne.
• This trial will test the effectiveness of a drug in a specific group of MND patients that have changes in a gene called unc13A. The trial is an international study with the Australian arm including 57 MND patients at 7 sites across the country.

2. PROJECThase 2 Clinical Trial – A placebo- controlled safety and efficacy of ambroxol in individuals with MND:

• The phase 2 trial aims to enrol 50 Australian patients at 5 sites across Australia in Sydney, Adelaide, Perth and Launceston.
• This trial is a long-term safety and efficacy studyof an already-approved drug re-purposed for MND.
• We tested ambroxol in multiple animal models of MND across different laboratories, showing a consistent benefit in motor function, muscle strength and motor neuron protection. This consistent effect across independent research teams provided convincing evidence that ambroxol may benefit MND.